Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | DPP4 | P27487 | 2/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5945366 | 1.00 | IDO1 (0.54) | IDO1DPP4F2AKT2OPRM1 | |
| SCHEMBL2149539 | 1.00 | IDO1 (0.54) | IDO1DPP4F2AKT2OPRM1 | |
| Hydrochloric Acid SCHEMBL2309180 | 0.98 | IDO1 (0.55) | IDO1DPP4F2AKT2OPRM1 | |
| Hydrochloric Acid SCHEMBL3323789 | 0.98 | IDO1 (0.55) | IDO1DPP4F2AKT2OPRM1 | |
| Hydrochloric Acid SCHEMBL18336573 | 0.98 | IDO1 (0.55) | IDO1DPP4F2AKT2OPRM1 | |
| Hydrochloric Acid SCHEMBL2309178 | 0.95 | IDO1 (0.50) | IDO1DPP4F2AKT2OPRM1 | |
| SCHEMBL8572567 | 0.91 | IDO1 (0.47) | IDO1DPP4F2AKT2OPRM1 | |
| SCHEMBL11885874 | 0.91 | IDO1 (0.50) | IDO1DPP4F2AKT2OPRM1 | |
| SCHEMBL2677106 | 0.91 | IDO1 (0.50) | IDO1DPP4F2AKT2OPRM1 | |
| SCHEMBL2677194 | 0.91 | IDO1 (0.55) | IDO1DPP4F2AKT2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293765-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| EP-1968944-A1 | ALKYLSULPHONAMIDE QUINOLINES | AstraZeneca AB (SE) | 2008-09-17 | — | — | EP | claimed |
| US-20080021062-A1 | Alkylsulphonamide Quinolines | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | US | claimed |
| WO-2007069977-A1 | ALKYLSULPHONAMIDE QUINOLINES | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | WO | claimed |
| US-20240174683-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4288437-A1 | MAP4K1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2023-12-13 | — | — | EP | disclosed |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2022167627-A1 | MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2022-08-11 | — | — | WO | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | MYOKARDIA INC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2021-06-10 | — | — | US | disclosed |
| WO-1995007926-A1 | ANDROSTENONES | GLAXO WELLCOME INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| CN-1085898-A | branched alkylamino derivatives of thiazoles, process for their preparation and pharmaceutical compositions containing them | SANOFI ELF (FR) | 1994-04-27 | — | — | CN | disclosed |
| US-5286509-A | L-aspartyl-D-α-aminoalkanoyl-(S)-N-alpha-alkylbenzyl amides useful as artificial sweeteners | THE COCA-COLA COMPANY (US) | 1994-02-15 | — | — | US | disclosed |
| US-4230878-A | AND 4-(UNSATURATED ALKYL)AMINOBENZOIC ACIDS AND DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1980-10-28 | — | — | US | disclosed |
| US-4227014-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4216217-A | FUNGICIDES, INSECTICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1980-08-05 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
| US-4107326-A | ANTIHYPERTENSIVE AGENTS, DIURETICS | AMERICAN CYANAMID COMPANY (US) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021062-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | IDO1 3774/4885DPP4 3603/4885F2 1631/4885 |
| US-20230091047-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | HAVCR2, HCCS, TYMP | IDO1 716/4885DPP4 2140/4885F2 957/4885 |
| US-20210346379-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | IDO1 3012/4885DPP4 1811/4885F2 4127/4885 |
| US-20080293765-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | IDO1 3508/4885DPP4 3580/4885F2 1876/4885 |
| US-20240174683-A1 | MAP4K1 INHIBITORS | MAP3K4, MAP4K4, MAP4K1 | IDO1 2223/4885DPP4 2337/4885F2 2471/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | IDO1 2554/4885DPP4 2202/4885F2 3949/4885 |
| US-20210171537-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | IDO1 3069/4885DPP4 1736/4885F2 4022/4885 |
| US-20230165860-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | IDO1 3012/4885DPP4 1811/4885F2 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.